Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 1
2017 2
2018 2
2019 3
2020 1
2021 4
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Wang C, et al. Among authors: morris b. Nature. 2019 Oct;574(7777):268-272. doi: 10.1038/s41586-019-1607-3. Epub 2019 Oct 2. Nature. 2019. PMID: 31578521 Free PMC article.
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J, Paes Dias M, Gogola E, Rolfs F, Piersma SR, de Bruijn R, de Ruiter JR, van den Broek B, Duarte AA, Sol W, van der Heijden I, Andronikou C, Kaiponen TS, Bakker L, Lieftink C, Morris B, Beijersbergen RL, van de Ven M, Jimenez CR, Wessels LFA, Rottenberg S, Jonkers J. Bhin J, et al. Among authors: morris b. Cell Rep. 2023 May 30;42(5):112538. doi: 10.1016/j.celrep.2023.112538. Epub 2023 May 19. Cell Rep. 2023. PMID: 37209095 Free PMC article.
Paradoxical activation of oncogenic signaling as a cancer treatment strategy.
Dias MH, Friskes A, Wang S, Fernandes Neto JM, van Gemert F, Mourragui S, Papagianni C, Kuiken HJ, Mainardi S, Alvarez-Villanueva D, Lieftink C, Morris B, Dekker A, van Dijk E, Wilms LHS, da Silva MS, Jansen RA, Mulero-Sanchez A, Malzer E, Vidal A, Santos C, Salazar R, Wailemann RAM, Torres TEP, De Conti G, Raaijmakers JA, Snaebjornsson P, Yuan S, Qin W, Kovach JS, Armelin HA, Te Riele H, van Oudernaarden A, Jin H, Beijersbergen RL, Villanueva A, Medema RH, Bernards R. Dias MH, et al. Among authors: morris b. Cancer Discov. 2024 Mar 27. doi: 10.1158/2159-8290.CD-23-0216. Online ahead of print. Cancer Discov. 2024. PMID: 38533987
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.
Hoefsmit EP, van Royen PT, Rao D, Stunnenberg JA, Dimitriadis P, Lieftink C, Morris B, Rozeman EA, Reijers ILM, Lacroix R, Shehwana H, Ligtenberg MA, Beijersbergen RL, Peeper DS, Blank CU. Hoefsmit EP, et al. Among authors: morris b. Cancer Immunol Res. 2023 Apr 3;11(4):450-465. doi: 10.1158/2326-6066.CIR-22-0494. Cancer Immunol Res. 2023. PMID: 36753604
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.
Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, Kuiken HJ, Morris B, Edwards F, Jochems F, van Tellingen O, Boeije M, Proost N, Jansen RA, Qin S, Jin H, Koen van der Mijn JC, Schepers A, Venkatesan S, Qin W, Beijersbergen RL, Wang L, Bernards R. Chen M, et al. Among authors: morris b. Cell Rep Med. 2024 Mar 19;5(3):101471. doi: 10.1016/j.xcrm.2024.101471. Cell Rep Med. 2024. PMID: 38508142 Free PMC article.
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.
Severson TM, Zhu Y, Prekovic S, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden M, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A, Wessels L, Corey E, Zwart W, Bergman AM. Severson TM, et al. Among authors: morris b. medRxiv [Preprint]. 2023 Feb 24:2023.02.24.23286403. doi: 10.1101/2023.02.24.23286403. medRxiv. 2023. PMID: 36865297 Free PMC article. Preprint.
Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Pogacar Z, Groot K, Jochems F, Dos Santos Dias M, Mulero-Sánchez A, Morris B, Roosen M, Wardak L, De Conti G, Velds A, Lieftink C, Thijssen B, Beijersbergen RL, Bernards R, Leite de Oliveira R. Pogacar Z, et al. Among authors: morris b. Life Sci Alliance. 2022 May 9;5(9):e202101348. doi: 10.26508/lsa.202101348. Print 2022 Sep. Life Sci Alliance. 2022. PMID: 35534224 Free PMC article.
Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance.
Schep R, Brinkman EK, Leemans C, Vergara X, van der Weide RH, Morris B, van Schaik T, Manzo SG, Peric-Hupkes D, van den Berg J, Beijersbergen RL, Medema RH, van Steensel B. Schep R, et al. Among authors: morris b. Mol Cell. 2021 May 20;81(10):2216-2230.e10. doi: 10.1016/j.molcel.2021.03.032. Epub 2021 Apr 12. Mol Cell. 2021. PMID: 33848455 Free PMC article.
Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.
Spanjaard A, Shah R, de Groot D, Buoninfante OA, Morris B, Lieftink C, Pritchard C, Zürcher LM, Ormel S, Catsman JJI, de Korte-Grimmerink R, Siteur B, Proost N, Boadum T, van de Ven M, Song JY, Kreft M, van den Berk PCM, Beijersbergen RL, Jacobs H. Spanjaard A, et al. Among authors: morris b. Nucleic Acids Res. 2022 Jul 22;50(13):7420-7435. doi: 10.1093/nar/gkac545. Nucleic Acids Res. 2022. PMID: 35819193 Free PMC article.
20 results